- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | GENELUX Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 12.01. | Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners | 4 | GlobeNewswire (USA) | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances | 352 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 08.01. | Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock | 5 | GlobeNewswire (USA) | ||
| 07.01. | Genelux kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 07.01. | Genelux announces proposed public offering | 1 | Seeking Alpha | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 07.01. | Genelux Corporation Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 05.01. | Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data | 3 | Investing.com | ||
| 05.01. | Genelux-Aktie: Positive Studiendaten stützen Kaufempfehlung von H.C. Wainwright | 3 | Investing.com Deutsch | ||
| 02.01. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Genelux Corp Appoints Jason Litten CMO | 3 | RTTNews | ||
| 02.01. | Genelux appoints Jason Litten as chief medical officer | 1 | Investing.com | ||
| 02.01. | Genelux beruft Jason Litten zum neuen Chief Medical Officer | 3 | Investing.com Deutsch | ||
| 02.01. | Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer | 136 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.... ► Artikel lesen | |
| 05.11.25 | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 125 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen | |
| 05.11.25 | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 21.10.25 | Lake Street Capital Markets initiates Genelux stock with Buy rating | 5 | Investing.com | ||
| 03.09.25 | GENELUX Corp - 8-K, Current Report | 5 | SEC Filings | ||
| 07.08.25 | Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates | 176 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen | |
| 07.07.25 | Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development | 221 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,070 | +7,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| IMMUNIC | 0,511 | -1,73 % | EQS-News: Immunic AG: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Conference/Study results
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing... ► Artikel lesen | |
| CURIS | 0,840 | -4,00 % | Curis, Inc.: Curis Provides Third Quarter 2025 Business Update | Management to host conference call and webcast today at 4:30 p.m. ET
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,298 | +1,25 % | BioXcel Therapeutics kündigt Meilenstein- und Halteprämien für Führungskräfte an | ||
| ESPERION | 2,800 | -2,81 % | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia | - Company to Receive $90 Million Total Payment - - Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL - ANN ARBOR, Mich., Nov.... ► Artikel lesen | |
| CYBIN | 5,050 | 0,00 % | Jefferies stuft Helus Pharma mit 'Buy' ein und sieht Kurspotenzial von 232 % | ||
| KYNTRA BIO | 6,850 | -2,84 % | FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum | Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen | |
| KARYOPHARM | 5,600 | +5,66 % | Cantor Fitzgerald startet Karyopharm-Bewertung mit "Overweight" | ||
| BIOLINERX | 2,225 | -5,32 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,420 | -0,82 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU | Committee
for
Medicinal
Products
for
Human
Use
(CHMP)
issues
a
positive
opinion following re-examination, which
will
be reviewed by
the... ► Artikel lesen | |
| EDESA BIOTECH | 0,915 | -3,68 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal Year 2025 Results | TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 4,350 | +3,33 % | Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer | ||
| BRIACELL THERAPEUTICS | 3,480 | -1,69 % | BriaCell Therapeutics Corp.: BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients | 9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 4,940 | +5,11 % | Sagimet Biosciences Inc.: Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne | SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,050 (+2,13 %) liegt der Kurs bei 2,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.